Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT06580145 · ClinicalTrials.gov registry record · Phase 2
Leucine in Midlife Depression
A Phase 2 study of Major Depression, sponsored by Emory University.
- Recruiting
- Registry status
- Phase 2
- Development phase
- 75
- Enrollment target
- 1
- Study location
NCT06580145: Recruiting Phase 2 study of Major Depression, sponsored by Emory University.
NCT06580145 is a Phase 2 study of Major Depression that is actively recruiting participants, run by Emory University. The registered enrollment target is 75 participants, below the 325-participant average among 28 other Major Depression trials with a reported enrollment target (77% lower). The trial reports 1 study location across 1 state. According to ClinicalTrials.gov, the official US trial registry.
The verdict
NCT06580145, a Phase 2 study of Major Depression, is actively recruiting participants, sponsored by Emory University.
- RECRUITING
- Registry status
- Phase 2
- Development phase
- 75 participants
- Enrollment target
- 1
- Study location
Study Summary
The study aims to investigate the effects of a 6-week leucine challenge on brain chemistry, connectivity, and behavior in people with midlife depression. The researchers will compare the leucine and an active comparator arm (lysine) for 6 weeks.
Primary Outcome
Change in glutamate measured by magnetic resonance spectroscopy (MRS) in the basal ganglia in the leucine challenged group compared with the lysine-challenged group.
Conditions Studied
Interventions
- DRUG L-leucine
- DRUG L-lysine
Study Locations (1)
Georgia
- Emory University Hospital - Atlanta
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 75 participants |
| Start Date | 2025-02-01 |
| Est. Completion | 2029-06 |
| Phase | Phase 2 |
What NCT06580145 shows while recruiting
NCT06580145 is an interventional study that assigns participants to a tested intervention. The registry caps enrollment at 75 participants, a relatively small participant target, below the 325-participant average among 28 other Major Depression trials with a reported enrollment target (77% lower).
The record links to 1 condition, with Major Depression appearing as the primary indexed condition, and to 2 interventions - of which L-leucine is the first listed.
NCT06580145 reports a single indexed study location in Georgia.
Frequently Asked Questions
What is clinical trial NCT06580145 about?
NCT06580145 is a clinical study titled "Leucine in Midlife Depression". The study aims to investigate the effects of a 6-week leucine challenge on brain chemistry, connectivity, and behavior in people with midlife depression. The researchers will compare the leucine and an active comparator arm (lysine) for 6 weeks.
What is the current status of trial NCT06580145?
This trial is currently recruiting. It is a Phase 2 study. The enrollment target is 75 participants. The study started on 2025-02-01. Estimated completion is 2029-06.
What conditions does trial NCT06580145 study?
This clinical trial studies the following conditions: Major Depression.
What interventions are being tested in trial NCT06580145?
The interventions under investigation include: L-leucine (DRUG), L-lysine (DRUG).
Who is sponsoring clinical trial NCT06580145?
This trial is sponsored by Emory University, which has 1,208 total clinical trials registered on ClinicalTrials.gov.
Where is trial NCT06580145 being conducted?
This trial has 1 study location across Georgia. Contact the study sites directly through ClinicalTrials.gov for enrollment availability.
Learn More About Clinical Trials
Similar trials for Major Depression
Matched on the same primary condition, ranked to surface studies in the same phase first, then by recruiting status, no relevance scoring or editorial curation.
Where NCT06580145's enrollment target sits among peer trials
75 16th of 28 higher than 12 of 28 other Major Depression trials
participants (enrollment target), bucketed by value
Each bar is a band; taller bars hold more other Major Depression trials. The dashed line + filled bar mark this entry. Hover or tap any bar for its full count and share, and where it sits relative to this entry.
Source ClinicalTrials.gov registry export · 2026-08-08
-
Ketamine Alcohol (in Treatment-Resistant Depression)
RECRUITING · Phase 2
-
Lexapro and Pramipexole and to Treat Major Depression
COMPLETED · Phase 2
-
Antidepressant Effects of the Glycine Receptor Antagonist AV-101 (4-chlorokynurenine) in Major Depressive Disorder
COMPLETED · Phase 2
-
Mechanism of Action Underlying Ketamine's Antidepressant Effects: The AMPA Throughput Theory in Patients With Treatment-Resistant Major Depression
RECRUITING · Phase 1
-
University of Iowa Interventional Psychiatry Service Patient Registry
RECRUITING
-
NIMH Rhythms and Blues Study: A Prospective Natural History Study of Motor Activity, Mood States, and Bipolar Disorder
RECRUITING
Nationwide trials with similar profiles
Cross-condition peers matched on enrollment target and registry start date, not the same-condition list above.
Similar enrollment target
- NCT01535430 · 75 participants
Assessment of Eloquent Function in Brain Tumor Patients
- NCT01542879 · 75 participants · Phase 1
Development of Radiation Free Whole Body Magnetic Resonance (MR) Imaging Technique for Staging Children With Cancer
- NCT02232191 · 75 participants · Phase 2
Immunologic Response to Pneumococcal Polysaccharide Vaccine in Splenic Injury Patients
- NCT02754544 · 75 participants · NA
Electrocorticography in Mapping Functional Brain Areas During Surgery in Patients With Brain Tumors
Similar registry start date
- NCT05962346 · started 2026-12 · NA
Fetal Endoscopic Tracheal Occlusion for Congenital Diaphragmatic Hernia
- NCT07125183 · started 2026-12 · Phase 2
Study on Efficacy and Tolerability of Weekly Doxorubicin in Elderly Patients With Advanced or Metastatic Leiomyosarcoma
- NCT07292298 · started 2026-11 · Phase 2
Phase 2 Single-Arm Rectal Cancer Brachytherapy for Patients With Low-Lying Residual Adenocarcinoma After Total Neoadjuvant Therapy to Improve Organ Preservation Rates
- NCT04263285 · started 2026-10 · NA
Treatment of Depression Post-SCI